Title:
3rd Oligonucleotides-based Therapeutics Conference
Date(s) And Time(s):
Mar 23 2010 8:00AM - Mar 25 2010 5:00PM
Location:
DoubleTree Hotel and Executive Meeting Center
8120 Wisconsin Avenue
Bethesda, MD 20814
Interest Area(s):
CMC,Clinical Research,Clinical Safety/Pharmacovigilance,Nonclinical
Overview:
FEATURED TOPICS
· Non-Clinical
· Chemistry, Manufacturing, and Controls (CMC)
· Clinical Development
· Oligonucleotide Safety Working Group Updates
Featured Keynote Speakers:
Mauro Ferrari, PhD, Professor and Chairman, Department of Nanomedicine and Biomedical Engineering, University of Texas Health Science Center at Houston
Richard DiMarchi, PhD, Professor and Gill Chair in Biomolecular Science, Indiana University
See Highlight Tab for further information.
Learning Objectives:
At the conclusion of this meeting, participants should be able to:
• Identify and discuss oligonucleotide-based therapeutic product development challenges and the relevant FDA, EU and Health Canada regulations
• Assess the challenges faced and the accomplishments made in the clinical development of oligonucleotide-based therapeutic drugs to meet unmet needs
• Describe and discuss the critical issues in the nonclinical development of oligonucleotides and what efforts from industry and regulatory authorities are
underway to address these issues
• Differentiate the special challenges associated with the development of synthetic oligonucleotides as compared to small molecules
• Assess properties of oligonucleotide-based therapeutics that present special challenges in development and the scientific approaches to overcoming those
challenges
• Recognize the achievements made in the field to date and share the vision of the benefits to patients that are possible
Target Audience:
This program will benefit professionals involved in
· Biotechnology
· Biologics
· Chemistry, manufacturing, and quality assurance
· Clinical, regulatory, and business development
· Drug discovery
· Vaccines
Event Code:
10010
Contact Information:
Contact Joanne Wallace at the DIA office by telephone +1-215-442-6180, fax +1-215-442-6199 or
email Joanne.Wallace@diahome.org.
|
Disclosure Policy:
It is Drug Information Association policy that all faculty participating in continuing education activities must disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. Faculty disclosures will be included in the course materials.
|
|
The most convenient airport is Reagan National Airport and attendees should make airline reservations as early as possible to ensure availability. The DoubleTree Hotel and Executive Meeting Center Bethesda is holding a block of rooms at the reduced rate below until February 28, 2010, for the DIA event attendees. Room availability at this rate is guaranteed only until this date or until the block is filled.
Single $199 Double $199
Please contact the DoubleTree Hotel and Executive Meeting Center Bethesda by telephone at +1-301-664-7309 and mention the DIA event. The hotel is located at 8120 Wisconsin Avenue, Bethesda, MD 20814, USA.
|
Meeting
| Charitable Nonprofit/Acad | $675.00 | | Standard | $1350.00 | | Government (Full Time) | $405.00 | | Student | $338.00 |
|
|
Mauro Ferrari, PhD, Professor and Chairman, Department of Nanomedicine and Biomedical Engineering, University of Texas Health Science Center at Houston
Dr. Mauro Ferrari serves as a Professor & Director, Center for NanoMedicine, Brown Foundation Institute of Molecular Medicine, Chairman, Department of Biomedical Engineering, University of Texas Health Science Center at Houston, Professor of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Professor of Bioengineering, Rice University, and President of the Alliance for NanoHealth, Houston TX. Dr. Ferrari received a PhD in Mechanical Engineering from U.C. Berkeley. Dr. Ferrari is a founder of biomedical nano/micro-technology in biomedical applications with more than 160 peer-reviewed journal articles, six books, more than 20 issued patents and about thirty more pending in the US and internationally. His career research and development portfolio totals over $50 million. Dr. Ferrari served as Special Expert on Nanotechnology at the National Cancer Institute in 2003-2005, providing leadership into the establishment of the NCI’s Alliance for Nanotechnology.
Richard DiMarchi, PhD, Professor and Gill Chair in Biomolecular Science, Indiana University
Dr. DiMarchi is former Group Vice President at Eli Lilly & Company where for more than two decades provided leadership in biotechnology, endocrine research and product development. Dr. DiMarchi is a cofounder of Ambrx, Inc. and Marcadia Biotech, and serves as a board member to Ambrx, Marcadia, Isis Pharmaceuticals, and Alba Therapeutics. He is also a scientific advisor to Epitome Biosciences, Kai Pharmaceuticals, Semafore Biotechnologies, and three venture funds; 5AM, TMP, and Twilight. Dr. DiMarchi is readily recognized for discovery and development of rDNA-derived Humalog® (LisProhuman insulin). He has published more than one hundred papers and is a co-inventor on numerous patents. He recently received the 2005 AAPS Career Research Achievement Award in Biotechnology, the 2006 ACS Earle B. Barnes Award for Leadership in Chemical Research Management, the 2006 ACS Gustavus Esselen Award for Chemistry in the Service of Public Interest, and the 2007 Wallace Carothers Award for Excellence in Polymer Sciences.
|
|
|